GlassScriptPhysician profile
James R Messer
NPI 1235365388
$5,166.33
in general payments reported to CMS, 2019-2025
26 companies · $914 in 2025
The $914 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $274 · 2021: $1,003 · 2022: $716 · 2023: $646 · 2024: $786 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177 · Travel and Lodging: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.98 |
| Travel and Lodging | $168.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,003.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $741.75 | 2019-2025 | |
| Abbvie INC. | $594.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $388.34 | 2019-2025 | Zerbaxa, Verquvo, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.64 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $295.11 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $281.43 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $251.34 | 2019-2023 | Camzyos |
| Gilead Sciences, INC. | $179.53 | 2021-2024 | |
| Arthrex, INC. | $168.88 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.11 | 2020-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $137.89 | 2019 | |
| Sk Life Science, INC. | $98.16 | 2025 | |
| Sunovion Pharmaceuticals INC. | $96.40 | 2019 | |
| Melinta Therapeutics, LLC | $78.02 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63.09 | 2019-2024 | Rybelsus, Ozempic |
| Allergan, INC. | $48.88 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $44.36 | 2019-2024 | Ultomiris |
| Boston Scientific Corporation | $29.95 | 2019-2020 | |
| Cvrx, INC. | $29.72 | 2022 | |
| Philips North America LLC | $28.50 | 2021-2022 | |
| Abbott Laboratories | $23.47 | 2024 | Mitraclip |
| Lundbeck LLC | $23.04 | 2019 | |
| Cmp Pharma, INC. | $22.15 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.09 | 2022 | |
| Electromed, INC. | $13.40 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Messer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.